Battery Ventures to Take Private Enzo Biochem in All-Cash Transaction

Ensysce Biosciences Acquires Cy Biopharma

August 6, 2026

Biotechnology

Ensysce Biosciences completed its acquisition of Cy Biopharma in a stock-for-stock merger. Concurrently, Ensysce entered into a definitive private placement financing expected to raise about $21.5 million at initial close, plus an additional up to $38.6 million upon a clinical milestone, to fund development of Cy Biopharma’s lead program CY200 for complex regional pain syndrome.

Merck KGaA to Acquire Bio-Techne for $11.3 Billion

June 25, 2026

Healthcare Services

Merck KGaA has entered a definitive agreement to acquire Bio-Techne for $73 per share in an all-cash transaction valued at about $11.3 billion (enterprise value). The deal is expected to close in late 2026 or early 2027, subject to regulatory approvals and Bio-Techne shareholder approval.

Rallybio Corporation to Acquire Avenzo Therapeutics in $215M Financing Deal

June 2, 2026

Biotechnology

Rallybio Corporation entered into a definitive merger agreement to acquire Avenzo Therapeutics, with the combined company expected to operate as Avenzo Therapeutics, Inc. and trade on Nasdaq under the ticker symbol AVZO. The transaction includes a concurrent, oversubscribed $215 million private placement with participation from healthcare institutional investors and mutual funds, and is expected to close in Q4 2026 subject to customary conditions.

Roche to Acquire 89bio for Up to $3.5 Billion

September 22, 2025

Pharmaceuticals

Roche has reached an agreement to acquire 89bio, a biopharmaceutical company focused on treatments for liver diseases and cardiometabolic conditions. The deal is expected to close in the fourth quarter of 2025, with an offered price of $14.50 per share in cash plus potential contingent value rights tied to performance milestones for pegozafermin.

BioMarin Pharmaceutical Completes Acquisition of Inozyme Pharma

May 16, 2025

Healthcare Services

BioMarin Pharmaceutical Inc. completed its all-cash acquisition of Inozyme Pharma, Inc. for $4.00 per share, valuing the deal at approximately $270 million. The transaction adds INZ-701, a late-stage enzyme replacement therapy being developed for ENPP1 Deficiency, to BioMarin’s enzyme therapies portfolio.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.